By Vela Diagnostics

Singapore (January 5, 2016) – Vela Diagnostics announced today that the Sentosa® SA HHV6 Quantitative PCR Test is now available as a CE-IVD product. The test is based on real-time PCR and is intended for use in the detection and quantitation of Human Herpesvirus 6 (HHV6) DNA from symptomatic patients as an aid in HHV6 diagnosis and the management of transplant or immunocompromised patients who have been diagnosed with HHV6 infection.

The Sentosa® HHV6 Quantitative PCR Test is validated on the fully automated workflow with Sentosa® SX101 for sample extraction and PCR reaction setup, and is used in conjunction with the Rotor-Gene® Q MDx 5plex HRM platform. The test is also validated on plasma, serum, cerebrospinal fluid and whole blood.

Vela Diagnostics has launched five other CE-IVD Quantitative PCR Tests in the Immunosuppression Panel, namely for CMV, EBV, HSV1/2, VZV and BKV. With the addition of HHV6 to the Immunosuppression Panel, Vela strives to provide a comprehensive solution to meet customers’ clinical and laboratory needs.

HHV-6 is the virus that most commonly causes the childhood disease roseola. It includes 2 genetically distinct forms: HHV-6A and HHV-6B. Infection in adults is seen primarily in immunocompromised hosts who have undergone solid-organ or stem cell transplantation or in those with HIV infection.

To inquire more on product performance data and technical presentation, please contact Global Product Management, gpm@veladx.com.

Visit here for ordering information.